相关实验视频

Updated: Jul 5, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

尼沃卢马布受体在效应器调节性T细胞上的占用预测了临床益处

Masahiro Hosonuma^1,2,3,4, Yuya Hirasawa⁴, Atsuo Kuramasu¹

¹Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Setagaya-Ku, Japan.

|January 23, 2024

概括

尼沃卢马布的使用情况

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
药理学药理学是一个学科.

背景情况:

像尼沃卢马布这样的免疫检查点抑制剂 (ICI) 已经改变了癌症治疗,但固体瘤的应答率仍然很低 (~10%-30%).
预测患者预后和免疫相关不良事件 (irAEs) 的预测因素对于优化ICI治疗至关重要.
编程细胞死亡蛋白1 (PD-1) 受体占用率 (RO) 通过PD-1 抑制剂可能与疗效和irAEs相关,但需要在T细胞子集中进行表征.

研究的目的:

调查不同T细胞群体中尼沃卢马布RO与患者预后之间的关联.
探索尼沃卢马布RO与癌症患者中irAEs的发展之间的关系.
确定PD-1 RO在尼沃卢马布治疗患者的特定T细胞子集的预后相关性.

主要方法:

在32名癌症患者的不同T细胞种群中分析nivolumab受体占用率 (RO).
PD-1 RO水平与临床益处和整体存活率的相关性.
与免疫相关不良事件 (irAEs) 的发生率相关的nivolumab RO的评估.

主要成果:

在获得临床益处的患者中,对效应器调节性T细胞 (eTregs) 的尼沃卢马布RO显著较低.
在eTregs上的PD-1占用率和全因死亡率之间发现了显著的负相关性.
在摘要中没有特别提到与RO相关的irAE发展.

结论:

在eTregs上的Nivolumab RO可以作为PD-1抑制剂治疗的预后生物标志物.
在eTregs上抑制PD-1/PD-ligand 1 (PD-L1) 信号传递可能会降低抗瘤作用.
需要进一步的研究来验证eTreg PD-1 RO作为ICI治疗中的预后指标.

关键词:

在PD-1/PD-L1信号传输中.效应器调节性T细胞的效应器免疫检查点抑制剂免疫检查点抑制剂这就是尼沃卢马布 (nivolumab).接收器占用率接收器占用率

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Quantitative Aspects of Drug-Receptor Interaction

Quantitative Aspects of Drug-Receptor Interaction

The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...